Vogt T
Dermatologische Klinik und Poliklinik, Universitätsklinikum Regensburg , Franz-Josef-Strauss-Allee 11, 63042, Regensburg.
Hautarzt. 2008 Mar;59(3):237-48; quiz 249-50. doi: 10.1007/s00105-008-1486-2.
Angiosarcomas are rare tumors accounting for 1-2% of all soft tissue sarcomas. Nonetheless a dermatologist needs to be knowledgeable about this tumor because the prognosis is particularly poor. Angiosarcoma favors superficial soft tissues and skin (60%) with a clear predilection for the head and neck region. The average age of the patients presenting with cutaneous angiosarcomas is around 70 years with a peak incidence in the 8th decade. However, some subtypes may occur in children and adolescents. Secondary angiosarcoma after tissue-conserving radiation therapy for carcinoma of the breast represents an increasing problem, both the differentiation between atypical vascular lesions and true aggressive angiosarcoma and the therapy are challenging. The prognosis for angiosarcoma patients is gloomy despite all therapeutic efforts. Only early therapy seems to influence the outcome at all. There are some established guidelines for the primary and palliative therapy. Interesting new options of biomodulatory and molecularly targeted therapy can be envisioned.
血管肉瘤是罕见肿瘤，占所有软组织肉瘤的1%-2%。尽管如此，皮肤科医生仍需了解这种肿瘤，因为其预后特别差。血管肉瘤好发于浅表软组织和皮肤（60%），尤其好发于头颈部区域。皮肤血管肉瘤患者的平均年龄约为70岁，发病高峰在80岁左右。然而，某些亚型可能发生于儿童和青少年。乳腺癌保乳放疗后继发性血管肉瘤是一个日益严重的问题，非典型血管病变与真正侵袭性血管肉瘤的鉴别以及治疗都具有挑战性。尽管进行了所有治疗努力，血管肉瘤患者的预后仍不容乐观。似乎只有早期治疗才能对结局产生影响。对于原发性和姑息性治疗有一些既定的指导原则。可以预想生物调节和分子靶向治疗有一些有趣的新选择。
